(Circulation. 2001;103:630.)
© 2001 American Heart Association, Inc.
Brief Rapid Communications |
Increased Angiotensin-Converting Enzyme Activity in Coronary Artery Specimens From Patients With Acute Coronary Syndrome
From the Division of Cardiology, Osaka Rosai Hospital, Sakai, Osaka, Japan.
Correspondence to Shiro Hoshida, MD, PhD, Chief, Division of Cardiology, Osaka Rosai Hospital, 1179-3 Nagasone-cho, Sakai, Osaka 591-8025, Japan. E-mail hoshidas{at}orh.go.jp
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionConclusionsReferences |
|---|
Background—Angiotensin-converting enzyme (ACE) inhibitors are effective in the secondary prevention of ischemic heart disease, but they do not reduce the rate of restenosis. Vascular ACE activity in the culprit coronary lesions of these patients, however, has never been quantified.
Methods and Results—We measured the ACE activity of vascular tissue obtained by directional coronary atherectomy in patients with acute coronary syndrome (n=17) and in patients with stable ischemic heart disease (n=36), with and without restenosis. The ACE activity of the culprit coronary lesions was significantly increased in patients with acute coronary syndrome (0.87±0.12 nmol · min–1 · mg protein–1; P<0.01) but not in patients with ischemic heart disease with restenosis (n=11, 0.19±0.05 nmol · min–1 · mg protein–1) when compared with those patients with ischemic heart disease without restenosis (n=25, 0.20±0.05 nmol · min–1 · mg protein–1). There was no difference between the ACE activity of the coronary tissue of the in-stent (n=5) and stent-unrelated (n=6) restenosis patients (0.24±0.10 versus 0.15±0.04 nmol · min–1 · mg protein–1). Serum ACE activity did not differ significantly among the patients.
Conclusions—The present study demonstrates increased ACE activity in culprit lesions in acute coronary syndrome, indicating that enhanced ACE activity is related to the causative mechanism of active coronary lesions.
Key Words: heart diseases • angiotensin • atherosclerosis • restenosis
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionConclusionsReferences |
|---|
Angiotensin-converting enzyme (ACE) inhibitors are effective in the secondary prevention of ischemic heart disease,1 but they do not reduce the rate of restenosis.2 3 Recently, increased immunohistochemical staining for ACE has been reported in atherosclerotic coronary tissue4 and in the culprit lesions of restenosis after balloon injury,5 and increased plasma ACE levels have been found in patients with in-stent restenosis.6 However, vascular ACE activity in culprit coronary lesions was never quantified. To test the hypothesis that the ACE activity of culprit coronary lesions is increased in unstable ischemic heart disease (IHD), we examined differences between ACE activity in coronary atherectomy specimens from patients with acute coronary syndrome (ACS) and stable IHD.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionConclusionsReferences |
|---|
Study Population
To obtain atherosclerotic plaque specimens from patients with symptomatic coronary artery disease, patients undergoing directional coronary atherectomy at Osaka Rosai Hospital who gave informed consent were included in the study. None of the patients had been taking ACE inhibitors. A total of 53 patients were enrolled: 17 patients (63±2 years) with de novo coronary stenosis presented with ACS (non–Q-wave infarction and unstable angina, Canadian Cardiovascular Society class III to IV), and 36 patients had stable IHD. In 25 of these 36 patients (63±1 years), symptoms were caused by de novo coronary lesions and, in the remaining 11 of the 36 patients (63±3 years), symptoms were due to restenotic lesions. Coronary specimens from ACS patients and from patients with IHD and restenosis were obtained within 1 week after admission and 5±1 months after percutaneous coronary intervention, respectively.
Interventional Procedure
All patients were pretreated with aspirin, 81 to 162
mg daily, before atherectomy. Concomitant medical therapy, such as
nitrates, calcium channel blockers, and ß-adrenergic blocking agents,
was continued at the discretion of the attending physician. Atherectomy
was performed with the femoral approach using 10F arterial sheaths and
guide catheters, and a directional coronary atherectomy catheter
(AtheroCath-GTO, Devices for Vascular Intervention, Inc) of
appropriate size to produce an approximate device-to-artery ratio of
1.1:1 was prepared. All atherectomy specimens were rapidly frozen in
liquid nitrogen. Blood was withdrawn from all patients early in the
morning on the day of catheterization.
Measurements of ACE Activity
ACE activity was measured using a previously reported
method7 with slight
modifications. Briefly, coronary tissue was homogenized on ice and
centrifuged for 20 minutes at
1500g (4°C). ACE was assayed
in a 250-µL final volume of a mixture of 100 mmol/L borate buffer (pH
8.3), 800 mmol/L NaCl, 50 µL of serum or tissue homogenate, and 3.5
mmol/L substrate (Hip-His-Leu,
benzyloxy-carbonyl-glycyl-histidyl-leucine). The mixture was incubated
at 37°C for 30 minutes (serum) or 120 minutes (tissue homogenates).
The His-Leu–liberated amount was measured fluorometrically, with
excitation at 360 nm and emission at 500 nm. ACE activity is expressed
as the rate of His-Leu production (nanomoles per minute per milligram
of protein). The protein content of the supernatant of the tissue
homogenates was determined using the method of Lowry et
al,8 with bovine serum
albumin as the standard. Hip-His-Leu and His-Leu were obtained from the
Peptide Institute.
Statistical Analysis
Values are expressed as means±SEM. The significance
of differences in the ACE activity of serum and coronary tissue or in
age was determined by ANOVA followed by Scheffe’s test, as
appropriate. The significance of differences in the baseline
characteristics was determined by 
2 test.
P<0.05 was considered
statistically significant.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionConclusionsReferences |
|---|
Patient Characteristics
The baseline clinical characteristics of the study population are shown in Table
.
The groups were generally well matched with respect to age, sex, and
coronary risk factors.
|
ACE Activity
ACE activity in coronary tissue was significantly
higher in patients with ACS (n=17, 0.87±0.12 nmol ·
min–1 · mg
protein–1,
P<0.01) than in those with
stable IHD, but it was not increased in coronary restenotic lesions
(n=11, 0.19±0.05 nmol · min–1 · mg
protein–1) compared with non-restenotic
lesions (n=25, 0.20±0.05 nmol · min–1
· mg protein–1;
Figure).
Different ACE activity was not observed in patients with in-stent (n=5)
or stent-unrelated (n=6) restenosis (0.24±0.10 versus 0.15±0.04 nmol
· min–1 · mg
protein–1,
P=0.072). The total protein
content of the coronary tissue did not differ significantly between the
groups (data not shown). There was no significant difference in serum
ACE activity between patients with ACS (n=17, 0.34±0.03 nmol ·
min–1 · mg
protein–1) and stable non-restenotic IHD
(n=25, 0.32±0.03 nmol · min–1 · mg
protein–1) or stable restenotic IHD (n=11,
0.31±0.03 nmol · min–1 · mg
protein–1).
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionConclusionsReferences |
|---|
The results of this study demonstrate increased ACE activity in the culprit coronary lesions of ACS patients but not in stable IHD patients. Increased accumulation of ACE has been reported in the atherosclerotic coronary arteries of IHD patients.4 The discrepancy between such reports and our own observations may be attributable to differences in the sites in the vessels selected to evaluate ACE activity: atherectomy samples mainly consist of the thickened intima of atherosclerotic arteries. ACE activity in the media and adventitia may increase in atherosclerotic arteries in stable IHD.
ACE activity in blood vessel specimens obtained from ACS patients was significantly increased, indicating a pathophysiological role of increased ACE activity in the instability of atherosclerotic plaque. This is not unexpected, because ACE is a known local mediator of inflammation, and unstable coronary plaques have a strong inflammatory composition. In particular, macrophages are common components of the unstable plaque, and these cells strongly upregulate ACE activity during differentiation. The increased ACE activity observed in this study, therefore, may be a consequence of the higher prevalence of inflammatory cells in the samples obtained from ACS patients. Colocalization of ACE, angiotensin II, and the angiotensin II type 1 receptor with macrophages has been observed at the shoulder lesion of coronary atherosclerotic plaques and in the atherectomy tissue of patients with unstable angina.9 Angiotensin II–induced cytokines9 and oxidative stress10 11 may play a role in plaque instability.
Increased ACE expression was observed in the thickened neointima of restenotic lesions in an experimental model of endothelial injury.12 In humans, however, the ACE activity of restenotic neointimal lesions in this study had not increased when measured 5±1 months after coronary intervention, although the sample size was small. The increased ACE expression after balloon injury may be time-dependent: Ohishi et al5 reported that ACE expression is increased during the first 2 months after coronary intervention. However, with in-stent restenosis, increased ACE expression has been shown to persist for as long as 6 months after intervention.13 In our study, the ACE activity did not differ significantly between in-stent and stent-unrelated restenosis, although the former value exhibited a tendency to be high (P=0.072). A high number of diabetic patients (42%, 22 of 53) may influence the tissue characteristics of the restenotic plaques found in this study.
|
Conclusions |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionConclusionsReferences |
|---|
The present study is the first to report differences between the vascular ACE activity of the culprit lesions of patients with ACS and stable IHD. We concluded that increased ACE activity in lumen-sided coronary tissues may be involved in the pathophysiology of ACS.
|
Acknowledgments |
|---|
This report was supported by the research fund from the Labor Welfare Corporation (to S. Hoshida, 2000), Kawasaki, Japan.
Received October 23, 2000; revision received December 13, 2000; accepted December 19, 2000.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionConclusionsReferences |
|---|
1. The SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement trial. N Engl J Med. 1992;327:669–673.[Abstract]
2.
The MERCATOR Study
Group. Does the new angiotensin converting enzyme inhibitor cilazapril
prevent restenosis after percutaneous transluminal coronary
angioplasty? Results of the MERCATOR study: a multicenter, randomized,
double blinded, placebo-controlled trial.
Circulation. 1992;86:100–110.
3. Faxon DP, the MARCATOR Study Group. Effect of the high dose angiotensin-converting enzyme inhibition on restenosis: final results of the MARCATOR study, a multicenter, double-blind, placebo-controlled trial of cilazapril. J Am Coll Cardiol. 1995;25:362–369.[Abstract]
4.
Diet F, Pratt RE,
Berry GJ, et al. Increased accumulation of tissue ACE in human
atherosclerotic coronary artery disease.
Circulation. 1996;94:2756–2767.
5.
Ohishi M, Ueda M,
Rakugi H, et al. Upregulation of angiotensin-converting enzyme during
the healing process after injury at the site of percutaneous
transluminal coronary angioplasty in humans.
Circulation. 1997;96:3328–3337.
6.
Ribichini F,
Steffenino G, Dellavalle A, et al. Plasma activity and
insertion/deletion polymorphism of angiotensin I-converting enzyme: a
major risk factor and a marker of risk for coronary stent restenosis.
Circulation. 1998;97:147–154.
7. Hoshida S, Nishida M, Yamashita N, et al. Vascular angiotensin-converting enzyme activity in cholesterol-fed rabbits: effects of enalapril. Atherosclerosis. 1997;130:53–59.[Medline] [Order article via Infotrieve]
8.
Lowry OH,
Rosenbrough NJ, Farr AL, et al. Protein measurement with the Folin
phenol reagent. J Biol
Chem. 1951;193:265–275.
9.
Schieffer B,
Schieffer E, Hilfiker-Kleiner D, et al. Expression of angiotensin II
and interleukin 6 in human coronary atherosclerotic plaques: potential
implications for inflammation and plaque instability.
Circulation. 2000;101:1372–1378.
10.
Griendling KK,
Minieri CA, Ollerenshaw JD, et al. Angiotensin II stimulates NADH and
NADPH oxidase activity in cultured vascular smooth muscle cells.
Circ Res. 1994;74:1141–1148.
11. Rajagopalan S, Kurz S, Munzel T, et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation: contribution to alterations of vasomotor tone. J Clin Invest. 1996;97:1916–1923.[Medline] [Order article via Infotrieve]
12. Rakugi H, Kim DK, Krieger JE, et al. Induction of angiotensin converting enzyme in the neointima after vascular injury: possible role in restenosis. J Clin Invest. 1994;93:339–346.
13.
Ribichini F,
Pugno F, Ferrero V, et al. Angiotensin-converting enzyme tissue
activity in the diffuse in-stent restenotic plaque.
Circulation. 2000;101:e33–e35.
This article has been cited by other articles:
 |
|
 |
|
  E. Zintzaras, G. Raman, G. Kitsios, and J. Lau Angiotensin-Converting Enzyme Insertion/Deletion Gene Polymorphic Variant as a Marker of Coronary Artery Disease: A Meta-analysis Arch Intern Med, May 26, 2008; 168(10): 1077 - 1089. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Heeneman, J. C. Sluimer, and M. J.A.P. Daemen Angiotensin-Converting Enzyme and Vascular Remodeling Circ. Res., August 31, 2007; 101(5): 441 - 454. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Ribichini, F. Pugno, V. Ferrero, G. Bussolati, M. Feola, P. Russo, C. Di Mario, A. Colombo, and C. Vassanelli Cellular Immunostaining of Angiotensin-Converting Enzyme in Human Coronary Atherosclerotic Plaques J. Am. Coll. Cardiol., March 21, 2006; 47(6): 1143 - 1149. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. L. Lazar Role of Angiotensin-Converting Enzyme Inhibitors in the Coronary Artery Bypass Patient Ann. Thorac. Surg., March 1, 2005; 79(3): 1081 - 1089. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. G. Neri Serneri, M. Boddi, P. A. Modesti, M. Coppo, I. Cecioni, T. Toscano, M. L. Papa, M. Bandinelli, G. F. Lisi, and M. Chiavarelli Cardiac Angiotensin II Participates in Coronary Microvessel Inflammation of Unstable Angina and Strengthens the Immunomediated Component Circ. Res., June 25, 2004; 94(12): 1630 - 1637. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Cipollone, M. Fazia, A. Iezzi, B. Pini, C. Cuccurullo, M. Zucchelli, D. de Cesare, S. Ucchino, F. Spigonardo, M. De Luca, et al. Blockade of the Angiotensin II Type 1 Receptor Stabilizes Atherosclerotic Plaques in Humans by Inhibiting Prostaglandin E2-Dependent Matrix Metalloproteinase Activity Circulation, March 30, 2004; 109(12): 1482 - 1488. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. J Wagenaar, A. J van Boven, A. C van der Wal, G. Amoroso, R. A Tio, C. M van der Loos, A. E Becker, and W. H van Gilst Differential localisation of the renin-angiotensin system in de-novo lesions and in-stent restenotic lesions in in-vivo human coronary arteries Cardiovasc Res, October 1, 2003; 59(4): 980 - 987. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Staniloae, A. J. Schwab, A. Simard, R. Gallo, I. Dyrda, G. Gosselin, J. Lesperance, J. W. Ryan, and J. Dupuis In vivo measurement of coronary circulation angiotensin-converting enzyme activity in humans Am J Physiol Heart Circ Physiol, January 1, 2003; 284(1): H17 - H22. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Schieffer Interaction of interleukin-6 and angiotensin II in atherosclerosis: culprit for inflammation? Eur. Heart J. Suppl., January 1, 2003; 5(suppl_A): A25 - A30. [Abstract] [PDF]
|
|
|
|
|
|
C. A. J. Farquharson and A. D. Struthers Gradual reactivation over time of vascular tissue angiotensin I to angiotensin II conversion during chronic lisinopril therapy in chronic heart failure J. Am. Coll. Cardiol., March 6, 2002; 39(5): 767 - 775. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Lapointe and J.-L. Rouleau Activation of vascular tissue angiotensin-converting enzyme (ACE) in heart failure: Effects of ACE inhibitors J. Am. Coll. Cardiol., March 6, 2002; 39(5): 776 - 779. [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Zhuo, F. A.O. Mendelsohn, and M. Ohishi Perindopril Alters Vascular Angiotensin-Converting Enzyme, AT1 Receptor, and Nitric Oxide Synthase Expression in Patients With Coronary Heart Disease Hypertension, February 1, 2002; 39(2): 634 - 638. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||